

## Special Issue

# Advances in Hematopoietic Stem Cell Research and Therapeutic Strategies for Thalassemia

### Message from the Guest Editors

Thalassemia is one of the most common genetic disorders globally, resulting from defects in hemoglobin production. It is associated with significant morbidity and mortality. In severe cases, regular blood transfusions combined with iron chelation therapy remain the standard treatment to manage the disease and prevent organ damage. Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) remains the only curative approach currently available for Thalassemia. However, its widespread use is limited by several challenges, including transplantation-related mortality (TRM), graft vs. host disease (GvHD), graft failure, high cost, and limited availability of suitable HLA-matched related donors. In the proposed Special Issue, we expect the following aspects to be covered:

- Recent advancements in allogeneic hematopoietic stem cell transplantation to cure Thalassemia.
- Autologous hematopoietic stem cell transplantation combined with gene therapy and gene editing to correct Thalassemia.
- Emerging insights into niche-HSC crosstalk within the Bone Marrow microenvironment to enhance the clinical outcome of HSCT.

---

### Guest Editors

Dr. Sandeep Yadav

Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Dr. Aloukick Kumar Singh

Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

---

### Deadline for manuscript submissions

30 March 2026



## Thalassemia Reports

---

an Open Access Journal  
by MDPI

---

Impact Factor 1.2



[mdpi.com/si/247934](https://mdpi.com/si/247934)

*Thalassemia Reports*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[thalassrep@mdpi.com](mailto:thalassrep@mdpi.com)

[mdpi.com/journal/  
thalassrep](https://mdpi.com/journal/thalassrep)





# Thalassemia Reports

---

an Open Access Journal  
by MDPI

---

Impact Factor 1.2



[mdpi.com/journal/  
thalassrep](https://mdpi.com/journal/thalassrep)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Aurelio Maggio

Department of Hematology and Oncology, Villa Sofia-Cervello Hospital,  
Palermo, Italy

---

#### Author Benefits

##### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

##### High Visibility:

indexed within ESCI (Web of Science), Embase, and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 44.7 days after submission; acceptance to publication is undertaken in 13.3 days (median values for papers published in this journal in the first half of 2025).